Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2025 (Event Date); Signed May 28, 2025
Context: The Company, a clinical-stage biopharmaceutical firm, announced a material definitive agreement for a private placement of equity securities and provided updates on clinical trial data.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Aggregate Gross Proceeds: Approximately $125 million (before offering expenses).
- Common Stock Issued: 14,130,313 shares at $6.50 per share.
- Pre-Funded Warrants Issued: 5,100,532 warrants to purchase common stock at $6.4999 per warrant.
- Warrant Terms: Exercise price of $0.0001 per share; immediately exercisable; subject to a 9.99% beneficial ownership limit (expandable to 19.99% with notice).
- Expected Closing Date: May 29, 2025.
- Use of Proceeds: Funding research and development of clinical-stage product candidates, research programs, working capital, and general corporate purposes.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. Investors should refer to the Form 10-Q for the quarter ended March 31, 2025, for historical financial data.
Material Changes and Agreements
- Lock-Up Agreement: Executive officers and directors agreed not to sell or transfer common stock or convertible securities for 60 days following the closing of the Private Placement, subject to exceptions for Rule 10b5-1 plans.
- Registration Rights: The Company agreed to file a registration statement with the SEC within 30 days of closing to register the resale of the shares and warrant shares, with efforts to keep it effective for up to two years.
- Exemption Status: The offering is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, sold only to accredited investors.
Outlook, Risks, and Unusual Items
- Clinical Update: On May 28, 2025, the Company announced dose escalation data for ORIC-944 in combination with apalutamide and darolutamide from its ongoing Phase 1b clinical trial.
- Forward-Looking Risks: Completion of the Private Placement is subject to customary closing conditions. Actual results may differ due to market conditions and other uncertainties.
- Regulatory Disclosure: Information regarding the press releases (Exhibits 99.1 and 99.2) is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final closing of the $125 million Private Placement on or around May 29, 2025.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification obligations.
- Examine the clinical data details in the May 28, 2025 press release (Exhibit 99.2) regarding ORIC-944.
- Check the upcoming registration statement filing (due within 30 days of closing) for resale registration of the new securities.
- Consult the most recent Form 10-Q for the quarter ended March 31, 2025, to assess current cash runway and burn rate prior to the new capital infusion.